[1]Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol,2016,27(4): 559-74.
[2]Boutros C, Tarhini A, Routier E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.LID - 10.1038/nrclinonc.2016.58 [J]. Nat Rev Clin Oncol,2016(6):12.
[3]EigentlerTK,HasselJC,BerkingC,etal.Diagnosis,monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy.Cancer Treat Rev,2016.(5):7-18.
[4]Daniel Y. Wang et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis. JAMA Oncology,2018(1):12.
